Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

22

Revenue 2014

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib

Two other FLT3 inhibitors - Daiichi Sankyo's quizartinib and Arog Pharma's crenolanib - are also in late-stage testing.

Daiichi drug hits mark in shingles pain, but misses in other indications

Daiichi drug hits mark in shingles pain, but misses in other indications Daiichi Sankyo's mirogabalin has shown efficacy in a phase III trial involving patients with post-herpetic neuralgia (PHN), the persistent and often excruciating pain that can follow shingles. ... What is clear however is that the results of the ALDAY

Novartis' Rydapt approval ends long AML therapy drought

Novartis' Rydapt approval ends long AML therapy drought Daiichi Sankyo's quizartinib - acquired along with Ambit Biosciences' for $410m in 2014 - and Arog Pharma's crenolanib are both in phase III testing in FLT3-positive AML.

Japanese pharma pulls no punches with post-Brexit UK

Japanese pharma pulls no punches with post-Brexit UK The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and

Deal Watch March 2017

Deal Watch March 2017 Resarci out-licensed ACAT-1 to Xynomic, as detailed above, and Daiichi Sankyo paid $4m upfront, committed $8m in research funding and further research, development and commercialisation milestone payments for the ... 20. Heptares/ Sosei Group. Daiichi

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

The_Pharma_Wars_Series.png
The Pharma Wars Series
The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
What pharma marketers can learn from growth hacking?
Growth hackers instinctively blend technical skills with creative thinking...
Medicines for Europe
The sound of silence puts the squeeze on generics and biosimilars
Medicines for Europe vows to get governments talking to realise potential...

Infographics